It has been recently announced by the Department of Science and Technology of Guangdong Province that the project entitled "Green Biological Manufacturing Technology and Application of Native Human Monoclonal Antibody Drugs" submitted by the Zhuhai Trinomab Biotech Co., Ltd. was awarded for funding as one of key projects for the "Green Biological Manufacturing" in the Key-Area Research and Development Program of Guangdong Province in 2021.
Key projects of "Green Biological Manufacturing" in the Key-Area Research and Development Program (KARDP) of Guangdong Province aim to break technical bottlenecks limiting the development of green manufacturing industry in Guangdong Province, to solve the issues and obstacles encountered in green manufacturing of critical products in short supply and to achieve production of critical pharmaceutical raw materials, bulk chemical products and polymeric materials by the large-scale bio-manufacturing and industrialization of biological synthesis process for fine chemicals. The overall goal of the KARDP is to establish a systemic supporting technology system for modern bio-manufacturing industry to enhance the ability and levels of innovation and green bio-manufacturing and to provide strong technical support for the high-quality development of manufacturing industry in Guangdong Province.
The awarded project “Green Biological Manufacturing Technology and Application of Native Human Monoclonal Antibody Drugs” intends to build a green bio-manufacturing technology and application system with high efficiency, high productivity, low cost, green as pollution-free technologies and process for discovery and development of monoclonal antibody therapeutics by using Trinomab's proprietary HitmAb® technology platform for research & evelopment and industrialization of native human monoclonal antibody technology. It will provide new means to meet the clinical needs in the areas of prevention and/or treatment of infectious diseases, autoimmune disorders and cancers and contribute to the high-quality development of the biomedical industry in Guangdong Province.
Trinomab Biotech Co., Ltd. is a clinical stage biopharmaceutical company with a global expansion perspective. The company is mainly engaged in R&D of novel fully native human monoclonal antibody (mAb) drugs. The core technology of the company is known as the fourth-generation antibody technology HitmAb®, a proprietary technology platform featuring differentiated advantages and high efficiency for the discovery of fully native human mAbs against infectious diseases, autoimmune disorders, malignant tumors and other human diseases.
Trinomab’s production site is located in Zhuhai International Health Harbor. Trinomab has built GMP compliant production facility with about 16,500m2 in space equipped with 1x 200L and 2 x 1000L scale antibody production lines with capacity of vial filling of approximately 300 vials/min and 25,000,000 vials/year. The production facility utilizes a new generation of innovative and smart manufacturing technology and the state of art information technology to support high quality bio-manufacturing of ongoing antibody therapeutic products needed for clinical trials and commercialization. Currently, production and filling of recombinant anti-tetanus toxin (TT) fully native human monoclonal antibody TNM002 injection as the world's first fully human monoclonal anti-tetanus toxin monoclonal antibody therapeutic drug for clinical phase III trials has been just completed. The facility can serve as production site with enough capacity for company’s needs in next 4-5 years of the development.
